Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature

摘要

SB4 (Benepali ), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel . In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etanercept patients, who gave consent, to SB4. A proportion of these patients switched back to Etanercept and therefore we aimed to investigate the reasons of SB4 withdrawal and compare our results with the current evidence.